:: Volume 13 - Covid 19 Supplement 2 ::
Caspian J Intern Med 2022, 13 - Covid 19 Supplement 2: 277-280 Back to browse issues page
Dexamethasone induced Sino-orbital Mucormycosis in a Patient Infected with COVID-19
Masoud Mardani , Ilad Alavi Darazam , Abdolreza Babamahmoodi
Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical, Tehran, Iran , rmmsabm@gmail.com
Abstract:   (1909 Views)
Background: The most common causes of immunodeficiency are iatrogenic and the result of the widespread use of therapies which modulates the immune system, whether they are planned or haphazardly. Mucormycosis is an invasive fungal disease which is usually secondary to immunosuppression, diabetic ketoacidosis, and long-term use of antibiotics, corticosteroids, and cytotoxic drugs. There are researches which show patients with coronavirus disease 2019 (COVID-19), especially severely ill or immunocompromised, are more likely to suffer from invasive fungal infections. Patients with diabetes are at a higher risk for severe COVID-19 outcomes. However, there has been no clear evidence on the relationship between pre-diabetes state and mucormycosis as a complication of SARS-CoV-2 infection so far.
Case Presentation: Here, we report a case of sino-orbital mucormycosis in a pre-diabetic 54-year-old female without any underlying diseases. The patient suffered from COVID-19 pneumonia. She received 8 mg dexamethasone for 12 days. Afterwards, she returned three days after her discharge with a complaint of pre-orbital cellulitis, unilateral facial numbness and decreased visual acuity. Therefore, after primary diagnostic imaging, she was regarded as a candidate for invasive surgical intervention and was consequently treated with a combination of liposomal amphotericin B, radical recurrent surgery and posaconazole.
Conclusion: It is very important to consider patients who are in the pre-diabetic state or possibly immunocompromised before prescribing steroids. The patients should be examined for invasive fungal infections in post-discharge period.
Keywords: COVID-19, Dexamethasone, Mucormycosis, SARS-CoV-2, Steroids
Full-Text [PDF 199 kb]   (553 Downloads)    
Type of Study: case report | Subject: Infectious Diseases
Received: 2021/01/5 | Accepted: 2021/12/12 | Published: 2022/04/6



XML     Print



Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 13 - Covid 19 Supplement 2 Back to browse issues page